Potapov Andrei Yuryevich

Potapov Andrei Yuryevich

Education

He graduated from Novosibirsk State University (Faculty of Economic Cybernetics), received additional economic education in the United States.

Career

1997-2007

Andrei Potapov began his career at Nicomed in 1997 as a financial manager in the Novosibirsk office of the company. In 2003, he became CFO for Russia and the CIS, and since 2007 he was Vice President and CFO of the company's CIS division.

2011-2014

In December 2011, Andrei Potapov was appointed General Director for Russia of the company "Nicomed," which became in September 2011. part of Japan's Takeda Pharmaceutical. Since January 1, 2013, Nicomed in Russia changed its name to Takeda (Takeda Pharmaceuticals LLC).

In September 2014, in addition to his post as General Director of Takeda Russia, Andrei Potapov was appointed head of the CIS territory, which includes Russia,, Kazakhstan Belarus Azerbaijan, Armenia, Georgia, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan and Mongolia.

2019-2020

Potapov's departure from the Russian representative office of Takeda became known at the beginning of 2019. Until March 2020, Andrei Potapov headed the ICMEA region (India, the Middle East, Turkey, Africa, Central Asia), and then left the company. Since September 2020, he has been developing startups in the field of IT solutions in the healthcare sector .

2023: Appointment as CEO of Stentex

In mid-March 2023, it became known about the appointment of Andrei Potapov as the new general director of the manufacturer of coronary stents "Stentex." In this position, he replaced Dmitry Belov. The relevant information is contained in the Unified State Register of Legal Entities (USRUL).

Stentex is engaged in localizing the production of coronary stents and catheters for the treatment of cardiovascular diseases. According to the official website, by March 2023, the manufacturer produces four types of products.^[1]

Notes